The week in health tech, explained in plain English.Get the free newsletter →
August 8, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

GSK Buys Nuvalent for $10.6B to Add Two Lung Cancer Drugs

By Healthcare Technology News ·

GSK is paying $10.6 billion to acquire Nuvalent, a biotech with two lead drugs aimed at non-small cell lung cancer (NSCLC), MedCity News reports. Both programs are under FDA review, and GSK says it plans to launch them this year if they win approval.

The two drugs target different driver mutations in NSCLC, the most common form of lung cancer. Precision oncology agents like these treat tumors defined by specific genetic alterations rather than by where the cancer originates, a strategy that has reshaped how late-stage lung cancer is managed. Nuvalent designed its candidates to overcome resistance and reach the brain, common weaknesses of earlier targeted therapies.

The deal continues a wave of large pharma buying late-stage oncology assets to refill pipelines ahead of looming patent expirations. For GSK, acquiring near-commercial drugs shortens the path to revenue and deepens its bet on targeted cancer treatment, a market where rivals including AstraZeneca and Pfizer are aggressively competing.

Sources

More in Finance

Finance

CMS Finalizes 2.3% FY2027 Pay Bumps for Rehab, Hospices

CMS finalized fiscal 2027 payment rules giving inpatient rehabilitation facilities and hospices each a 2.3% payment increase.

Why it matters: Thin Medicare increases set the revenue baseline for rehab and hospice operators already squeezed by labor and supply costs.

Finance

Crystalys Raises $130M for Gout Drug Dotinurad

Crystalys Therapeutics raised $130 million to advance its URAT1 inhibitor dotinurad through pivotal gout trials.

Why it matters: Fresh capital and a $950M Sobi deal show pharma is finally targeting gout, a common condition with few effective treatment options.

Finance

Hospital Margins Slip 5% as Profitability Divide Widens

Hospital operating margins fell 5% nationally in early 2026, deepening a profitability divide between smaller hospitals and large nonprofit systems.

Why it matters: A widening margin gap determines which hospitals can invest, consolidate, or survive, reshaping access and competition across the industry.